1. Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines Transparency Alliance 16/04/20091

2. The MeTA “model” Goal: increased access to essential medicines Purpose: Test if multi-stakeholder approach increases transparency, governance, efficiency and accountability, and encourages responsible business practices. MeTA12/03/20162

3. Medicines? 1/3 of the world’s population (2 billion people!) still have no access to good quality, essential medicines Gross inefficiencies in drug supply systems Governments alone cannot provide the service 16/04/2009 3

4. Transparency? Improving information access, scrutiny and use, in order to support the development of viable, efficient medicines markets and supply systems that benefit all developing country consumers – Transparency = not only disclosure of the price, quality, availability and promotion of medicines – But also how to use the information to identify barriers, and to agree on solutions – Accounting and Accountability

5. Drug Supply – Transparent? Source: SSDS Inc for the World Bank

6. Alliance? Global multi-stakeholder alliance – DFID – WHO – World Bank – Private Sector (pharmaceutical Industry, generic and local manufacturers, wholesalers, retailers etc) – Civil Society (public health, transparency, accountability and rights NGOs, grassroots networks, patients/consumer organisations, academia) – Seven MeTA pilot countries (incl. Kyrgyz Republic!)

7. What does MeTA want to do? Improve transparency and accountability on: – Price – Quality – Availability – Promotion Promote more: – Efficient supply chains – Affordable medicines – Equitable access – Rational use of medicines 16/04/2009 7

8. 7 Pilot Countries … pioneers, leaders, champions and innovators! 16/04/2009 8 … pioneers, leaders, champions and innovators!

9. Country Commitments Establish an effective multi-stakeholder forum Progressive disclosure of data in four areas Quality Regulatory, sourcing, quality assurance, vigilance Availability Supply chain operations, equitable access PriceSupplier, wholesaler, retailer, import taxes, duties, affordability PromotionObjective information,Rational use, good and ethical advertising and promotion 16/04/2009 9

10. MeTA phase 1: March 2008- Sept 2010 MeTA Global launches: – 15 May 2008 London, 21 May 2008 WHO Assembly Activities in all 7 pilot countries – MeTA Secretariat, WHO, World Bank can provide TA – GBP 100,000 / year support – Civil Society Capacity Strengthening Grant for CSO coalition up to GBP 50,000 Global feed-back meeting Feb 2010 External evaluation March 2010 If positive, DFID’s commitment for Phase 2 of MeTA:10 years

11. Congratulations! Congratulations and best wishes to MeTA Kyrgyzstan and its stakeholders on the launch of the MeTA Project! 16/04/2009 11 International MeTA Secretariat

12. 16/04/200912 More information? Wilbert Bannenberg, wilbert@metasecretariat.org Elodie Brandamir, ebrandamir@metasecretariat.org International Secretariat, info@metasecretariat.org MeTA website: www.MedicinesTransparency.org